207_Combined course Presentations
New perspectives and future directions: Is there a role for “mAbs” and immunotherapy in SCLC ?
Potential “targets of treatment”: Notch FGFR PI3KCA
RET FAK CXCR4 PARP PD-L1 VEGFR
Bunn Jr PA. et al. J Thor Oncol 2016;11
Made with FlippingBook